Oryzon Genomics SA, one of the darlings of the Spanish stock market, has suffered a setback after Roche pulled the plug on a partnership to develop a potential first-in-class cancer compound.
Spanish Biotech Star Oryzon Slumps After Roche Rejection
Barcelona-based Oryzon Genomics remains upbeat about the prospects for 'a first-in-class, best-in-class LSD1 inhibitor' for cancer even though Roche has walked away from what was a potentially lucrative partnership.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.